PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Biotechnologie

Mr. Jonny  Missulawin

Chief Financial Officer

Mr. Ori  Warshavsky

Chief Operating Officer - US

Ms. Dalit  Hazan

Executive Vice President of R&D and Clinical & Regulatory Affairs

Mr. Tal  Vilnai

General Counsel & Corporate Secretary

Ms. Dikla  Czaczkes Akselbrad

Chief Executive Officer & Director

Ms. Maria  Rubin

Vice President of Operations

Ms. Rivi  Lev-ari

Vice President of Human Resource

Dr. Jean-Marc  Hagai Pharm.D.

Chief Commercial Officer

Name	Marktkapitalisierung
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
Gubra A/S	0M
CytoTools AG	0M
Shanghai Haohai Biological Technology Co., Ltd.	0M
Purple Biotech Ltd.	0M
Starpharma Holdings Limited	0M

PolyPid Ltd.

PolyPid Ltd. Liste der Konkurrenten

Wichtigste Wettbewerber